References
- Lu GW, Warner KS, Wang F. Chapter 12. Development of pilosebaceous unit-targeted drug products. In: Shah VP, Maibach HI, Jenner J, editors. Topical drug bioavailability, bioequivalence, and penetration. 2nd ed. New York (NY): Springer, 2014. p. 181–216.
- Erstad M, Edwards C. Chapter 3. Topical drug products - development, manufacture and regulatory issues. In: Shargel L, Kanfer I, editors. Generic drug development: specialty dosage forms. 1st ed. Bocca Raton (BR): CRC Press, 2010. p. 28–53.
- Ethier A, Bansal P, Baxter J, et al. The role of excipients in the microstructure of topical semisolid drug products. In: Langley N, Michniak-Kohn B, Osborne DW, editors. The role of microstructure in topical drug product development. AAPS Advances in the Pharmaceutical Sciences Series. Cham, Switzerland: AAPS Springer, 2019. p. 155–193.
- Raghavan L, Brown M, Michniak-Kohn B, et al. In vitro release tests as a critical quality attribute in topical product development. In: Langley N, Michniak-Kohn B, Osborne DW, editors. The role of microstructure in topical drug product development. AAPS Advances in the Pharmaceutical Sciences Series. Cham, Switzerland: AAPS Springer, 2019. p. 47–87.
- Shah VP, Yacobi A, Lane ME. Chapter 23. Bioequivalence, quality, and novel assessment technologies for topical products: current challenges and future prospects. In: Shah VP, Maibach HI, Jenner J, editors. Topical drug bioavailability, bioequivalence, and penetration. 2nd ed. New York (NY): Springer, 2014. p. 389–398.
- US-FDA. Guidance for industry. Topical dermatological corticosteroids. In vivo bioequivalence. Bethesda, MD; 1995 June 2. Available from: https://www.fda.gov/media/70931/download
- US-FDA. Guidance for industry. Nonsterile semisolid dosage forms. Scale-up and post approval changes. Chemistry, manufacturing and controls. In vitro release testing and in vivo bioequivalence documentation. Bethesda (MD); 1997 May 7. Available from: https://www.fda.gov/media/71141/download.
- US-FDA. Draft guidance. Topical dermatological drug product NDAs and ANDAs - In vivo bioavailability, bioequivalence, in vitro release, and associated studies. 1998 June 02.
- European Medicine Agency. Committee for Medicinal Products for Human use (CHMP). Draft guideline on quality and equivalence of topical products. London (UK); 2018 December 14. Available from: https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-quality-equivalence-topical-products_en.pdf.
- United States Pharmacopoeia 41 - National Formulary 36, 2018. Chapter 1724: semisolid drug products - performance tests, United States Pharmacopeial Convention, Rockville, MD 20852.
- Ueda CT, Shah VP, Derdzinski K, et al. The topical/transdermal ad hoc advisory panel for the USP performance tests of topical and transdermal dosage forms: topical and transdermal drug products. Pharm Forum. 2009;35(3):750–755.
- US-FDA. Draft guidance on acyclovir ointment; 2012 March. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm296733.pdf.
- US-FDA. Draft guidance on acyclovir cream; recommended 2014 December; revised 2016 December. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm428195.pdf.
- Shah VP, Yacobi A, Rădulescu FŞ, et al. A science based approach to topical drug classification system (TCS). Int J Pharm. 2015;491(1–2):21–25.
- Tiffner KI, Kanfer I, Augustin T, et al. A comprehensive approach to qualify and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5. Int J Pharm. 2018;535(1–2):217–227.
- Pillai R, Shah V, Abriola L, et al. Release of hydrocortisone from a cream matrix: dependency of release on suspension concentration and measurement of solubility and diffusivity. Pharm Dev Technol. 2001;6(3):373–384.
- Zatz JL, Segers D. Techniques for measuring in vitro release from semisolids. Dissolution Technol. 1998;5(1):3–17.
- Shah VP, Rădulescu FŞ, Miron DS, et al. Commonality between BCS and TCS. Int J Pharm. 2016;509(1–2):35–40.
- European Medicine Agency. Committee for Medicinal Products for Human use (CHMP). Concept paper on the development of a guideline on quality and equivalence of topical products. London, UK; 2014 April 22. Available from: https://www.ema.europa.eu/documents/scientific-guideline/concept-paper-development-guideline-quality-equivalence-topical-products_en.pdf.
- Trottet L, Owen H, Holme P, et al. Are all aciclovir cream formulations bioequivalent? Int J Pharm. 2005;304(1–2):63–71.
- Nallagundla S, Patnala S, Kanfer I. Comparison of in vitro release rates of acyclovir from cream formulations using vertical diffusion cells. AAPS PharmSciTech. 2014;15(4):994–999.
- Krishnaiah YSR, Xu X, Rahman Z, et al. Development of performance matrix for generic product equivalence of acyclovir topical creams. Int J Pharm. 2014;475(1–2):110–122.
- Kamal NS, Krishnaiah YSR, Xu X, et al. Identification of critical formulation parameters affecting the in vitro release, permeation, and rheological properties of the acyclovir topical cream. Int J Pharm. 2020;590:119914.